American Journal of Hematology

Article	Citations
Hematological findings and complications of COVID‐19	1204
Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management	481
Hematologic parameters in patients with COVID‐19 infection	326
Thrombocytopenia following Pfizer and Moderna SARS‐CoV‐2 vaccination	307
Thrombosis in COVID‐19	217
Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring	207
Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk‐stratification and management	198
Primary myelofibrosis: 2021 update on diagnosis, risk‐stratification and management	183
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management	178
Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures	141
BNT162b2 COVID‐19 vaccine is significantly less effective in patients with hematologic malignancies	136
2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management	135
Age‐dependent and gender‐dependent antibody responses against SARS‐CoV‐2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine	124
Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management	113
Intermediate‐dose anticoagulation, aspirin, and in‐hospital mortality in COVID‐19: A propensity score‐matched analysis	112
Prolonged in‐hospital stay and higher mortality after Covid‐19 among patients with non‐Hodgkin lymphoma treated with B‐cell depleting immunotherapy	104
Efficacy and safety of CD19‐directed CAR‐T cell therapies in patients with relapsed/refractory aggressive B‐cell lymphomas: Observations from the JULIET, ZUMA	101
Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management	99
Morphological anomalies of circulating blood cells in COVID‐19	95
Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure	95
Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment	93
Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow‐up from a phase 1b study	89
Immune thrombocytopenia in a 22‐year‐old post Covid‐19 vaccine	89
Commercial anti‐CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center	87
Rapid and severe Covid‐19 pneumonia with severe acute chest syndrome in a sickle cell patient successfully treated with tocilizumab	81

Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients	80
Critically ill COVID‐19 infected patients exhibit increased clot waveform analysis parameters consistent with hypercoagulability	76
Acute myeloid leukemia: 2021 update on risk‐stratification and management	72
Leukoerythroblastic reaction in a patient with COVID‐19 infection	70
Vaso‐occlusive crisis and acute chest syndrome in sickle cell disease due to 2019 novel coronavirus disease (COVID‐19)	67
World Health Organization‐defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management	66
Marked factor V activity elevation in severe COVID‐19 is associated with venous thromboembolism	65
POEMS syndrome: 2021 Update on diagnosis, risk‐stratification, and management	65
C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab	64
Impact of sickle cell disease on patientsʼ daily lives, symptoms reported, and disease management strategies: Results from the international Sickle Cell World Assessment Survey (SWAY	64
Hodgkin lymphoma: A 2020 update on diagnosis, risk‐stratification, and management	64
Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring	64
Combination of CD19 and CD22 CAR‐T cell therapy in relapsed B‐cell acute lymphoblastic leukemia after allogeneic transplantation	60
Targeting BCL‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma	60
Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment‐related mortality	57
COVID‐19 pneumonia as a cause of acute chest syndrome in an adult sickle cell patient	57
COVID‐19 and mycoplasma pneumoniae coinfection	55
Immune thrombocytopenia (ITP) World Impact Survey (iWISh): Patient and physician perceptions of diagnosis, signs and symptoms, and treatment	52
Hepcidin levels predict Covid‐19 severity and mortality in a cohort of hospitalized Italian patients	51
Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management	50
Dramatic improvement after tocilizumab of severe COVID‐19 in a child with sickle cell disease and acute chest syndrome	50
Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) ‐ outcomes and mutation profile from venetoclax resistant MCL patients	50
Recommendations for diagnosis and treatment of methemoglobinemia	50
Acute lymphoblastic leukemia: A population‐based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1	49
Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy	48
Increased sFLT‐1/PlGF ratio in COVID‐19: A novel link to angiotensin II‐mediated endothelial dysfunction	48
SARS‐CoV‐2‐reactive antibody detection after SARS‐CoV‐2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell	48
Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and management	47
The first case of acquired hemophilia A associated with SARS‐CoV‐2 infection	46
SARS‐CoV‐2 infection in beta thalassemia: Preliminary data from the Italian experience	46
Immune thrombocytopenia (ITP) World Impact Survey (I‐WISh): Impact of ITP on health‐related quality of life	46
Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1‐JAK2, BCR‐JAK2 and ETV6‐ABL1 fusion genes	45
Mantle cell lymphoma in 2022—A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments	45
Ineffectiveness of high‐dose methotrexate for prevention of CNS relapse in diffuse large B‐cell lymphoma	45
Increased blood viscosity and red blood cell aggregation in patients with COVID‐19	44
Genotype‐phenotype correlation and molecular heterogeneity in pyruvate kinase deficiency	44
Primary myelofibrosis: 2023 update on diagnosis, risk‐stratification, and management	44
Venetoclax with azacitidine or decitabine in blast‐phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases	43
Outcome of T‐cell acute lymphoblastic leukemia/lymphoma: Focus on near‐ETP phenotype and differential impact of nelarabine	43
The use of venetoclax‐based salvage therapy for post‐hematopoietic cell transplantation relapse of acute myeloid leukemia	43
Granulocyte‐colony stimulating factor in COVID‐19: Is it stimulating more than just the bone marrow?	42
Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castlema	42
Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory T‐cell acute lymphoblastic leukemia/lymphoma. A CAMPUS ALL study	41
Hematologic parameters in patients with COVID‐19 infection: a reply	41
Cerebral venous thrombosis post BNT162b2 mRNA SARS‐CoV‐2 vaccination: A black swan event	40
Whole blood viscosity and red blood cell adhesion: Potential biomarkers for targeted and curative therapies in sickle cell disease	39
Hypercoagulability, endotheliopathy, and inflammation approximating 1 year after recovery: Assessing the long‐term outcomes in COVID‐19 patients	37
Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment	37
2021 clinical trials update: Innovations in hemophilia therapy	37
2021 update on clinical trials in β‐thalassemia	37

Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of Eu	36
Epidemiology, clinical picture and long‐term outcomes of FIP1L1‐PDGFRA‐positive myeloid neoplasm with eosinophilia: Data from 151 patients	36
Outcome of infection with omicron SARS‐CoV‐2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report	36
Heparin induced thrombocytopenia antibodies in Covid‐19	36
Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management	35
High‐dose dexamethasone plus recombinant human thrombopoietin vs high‐dose dexamethasone alone as frontline treatment for newly diagnosed adult primary immune thrombocytopenia: A prospective, multicen	35
COVID‐19 vaccines and risks of hematological abnormalities: Nested case–control and self‐controlled case series study	35
Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies	35
Blood and blood product use during COVID‐19 infection	34
Roxadustat for the treatment of anemia in patients with lower‐risk myelodysplastic syndrome: Open‐label, dose‐selection, lead‐in stage of a phase 3 study	34
Late‐onset hematological complications post COVID‐19: An emerging medical problem for the hematologist	34
Plasmacytoid lymphocytes in SARS‐CoV‐2 infection (Covid‐19)	34
Moderate fixed‐dose hydroxyurea for primary prevention of strokes in Nigerian children with sickle cell disease: Final results of the SPIN trial	34
First‐line treatment of double‐hit and triple‐hit lymphomas: Survival and tolerance data from a retrospective multicenter French study	32
Impaired response to first SARS‐CoV‐2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib	30
Optimizing the diagnostic workflow for acute lymphoblastic leukemia by optical genome mapping	30
Myelodysplastic syndromes with ring sideroblasts (MDS‐RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN‐RS‐T) – “2021 u	29
Treatment‐free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors	29
Recent advances in the pathophysiology of PIEZO1‐related hereditary xerocytosis	28
Outcome of patients with Fanconi anemia developing myelodysplasia and acute leukemia who received allogeneic hematopoietic stem cell transplantation: A retrospective analysis on behalf of EBMT	28
Real‐Life experience with hydroxyurea in patients with sickle cell disease: Results from the prospective ESCORT‐HU cohort study	28
Comprehensive phenotyping of erythropoiesis in human bone marrow: Evaluation of normal and ineffective erythropoiesis	27
High rate of profound clonal and renal responses with daratumumab treatment in heavily pre‐treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate	27
Expert‐level automated malaria diagnosis on routine blood films with deep neural networks	27
Cell‐type‐specific insights into iron regulatory processes	27
Classification of myeloid neoplasms/acute leukemia: Global perspectives and the international consensus classification approach	26
Venetoclax combined with FLAG‐IDA induction and consolidation in newly diagnosed acute myeloid leukemia	26
The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms	26
Prognostic factors and long‐term follow‐up of basiliximab for steroid‐refractory acute graft‐versus‐host disease: Updated experience from a large‐scale study	26
EBV‐positive diffuse large B‐cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk‐stratification, and management	26
Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia	26
Large granular lymphocytic leukemia – A retrospective study of 319 cases	25
Familial thrombocytopenia flare‐up following the first dose of mRNA‐1273 Covid‐19 vaccine	25
Revisiting the non‐transfusion‐dependent (NTDT) vs. transfusion‐dependent (TDT) thalassemia classification 10 years later	25
Risk‐based, response‐adapted therapy for early‐stage extranodal nasal‐type NK/T‐cell lymphoma in the modern chemotherapy era: A China Lymphoma Collaborative Group study	25
Comparative effectiveness and safety of anticoagulants for the treatment of heparin‐induced thrombocytopenia	25
WHO defined chronic eosinophilic leukemia, not otherwise specified (CEL, NOS): A contemporary series from the Mayo Clinic	25
Circulating endothelial cells in COVID‐19	24
Persistence of Ad26.COV2.S‐associated vaccine‐induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies	24
Real‐world effectiveness of eliglustat in treatment‐naïve and switch patients enrolled in the International Collaborative Gaucher Group Gaucher Registry	24
Laboratory testing for ADAMTS13: Utility for TTP diagnosis/exclusion and beyond	24
Treatment outcomes and prognostic factors of patients with adult Langerhans cell histiocytosis	24
Gene therapies for transfusion dependent β‐thalassemia: Current status and critical criteria for success	24
Pregnancy outcomes with hydroxyurea use in women with sickle cell disease	24
Comparison of therapy‐related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study	24
Hairy cell leukemia 2022: Update on diagnosis, risk‐stratification, and treatment	24
A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes	24
Randomized control trial of oral arginine therapy for children with sickle cell anemia hospitalized for pain in Nigeria	23
Outcomes of TP53‐mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival	23
The emergence of methemoglobinemia amidst the COVID‐19 pandemic	23
Prediction of early (4‐week) mortality in acute myeloid leukemia with intensive chemotherapy	23
Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression‐free survival and early treatment failure af	23
Myeloid and lymphoid vacuolation in VEXAS syndrome	23
Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia	23
Localized immunoglobulin light chain amyloidosis: Novel insights including prognostic factors for local progression	23
Serologic response to mRNA COVID‐19 vaccination in lymphoma patients	23
Upgrading the evidence for the use of ambroxol in Gaucher disease and GBA related Parkinson: Investigator initiated registry based on real life data	23
Characterization of the rate, predictors, and thrombotic complications of thrombocytosis in iron deficiency anemia	23
Chimeric antigen receptor T‐cells, bispecific antibodies, and antibody‐drug conjugates for multiple myeloma: An update	22
Fresh vs. frozen allogeneic peripheral blood stem cell grafts: A successful timely option	22
Treatment and disease‐related complications in multiple myeloma: Implications for survivorship	22
Patient‐reported outcomes in sickle cell disease and association with clinical and psychosocial factors: Report from the sickle cell disease implementation consortium	22
Venetoclax and hypomethylating agents in FLT3‐mutated acute myeloid leukemia	22
Daratumumab‐lenalidomide‐dexamethasone vs standard‐of‐care regimens: Efficacy in transplant‐ineligible untreated myeloma	21
Fecal microbiota transplantation in patients with acute and chronic graft‐versus‐host disease—spectrum of responses and safety profile. Results from a prospective, multicenter study	21
An artificial intelligence‐assisted diagnostic platform for rapid near‐patient hematology	21
Anti‐CD19 and anti‐BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem‐cell transplantation for high‐risk newly diagnosed multiple myeloma	21
Oxygen gradient ektacytometry‐derived biomarkers are associated with vaso‐occlusive crises and correlate with treatment response in sickle cell disease	21
Cytogenetic and molecular abnormalities in Waldenström's macroglobulinemia patients: Correlations and prognostic impact	21
Phase 1 study of combinatorial sorafenib, G‐CSF, and plerixafor treatment in relapsed/refractory, FLT3‐ITD‐mutated acute myelogenous leukemia patients	21
Follicular lymphoma: 2023 update on diagnosis and management	21
Cutaneous T‐cell lymphomas: 2021 update on diagnosis, risk‐stratification, and management	21
Methotrexate and cytarabine for adult patients with newly diagnosed Langerhans cell histiocytosis: A single arm, single center, prospective phase 2 study	21
Myeloproliferative neoplasms and pregnancy: Overview and practice recommendations	21
Successful treatment of thrombotic thrombocytopenia with cerebral sinus venous thrombosis following Ad26.COV2.S vaccination	21
Safety and feasibility of hematopoietic progenitor stem cell collection by mobilization with plerixafor followed by apheresis vs bone marrow harvest in patients with sickle cell disease in the multi‐c	21
Glucose‐6‐phosphate dehydrogenase deficiency‐associated hemolysis and methemoglobinemia in a COVID‐19 patient treated with chloroquine	20
Optical genome mapping for structural variation analysis in hematologic malignancies	20
Evaluation of the prothrombin fragment 1.2 in patients with coronavirus disease 2019 (COVID‐19)	20
Care of patients with hemoglobin disorders during the COVID‐19 pandemic: An overview of recommendations	20

2021 Update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management	20
Treatment of upper extremity deep vein thrombosis with apixaban and rivaroxaban	20
SARS‐CoV‐2 vaccination in patients with autoimmune cytopenias: The experience of a reference center	20
Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric‐like GIMEMA LAL‐1308 trial	20
Role of imaging in multiple myeloma	20
Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results	20
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK)‐positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy	20
Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in sickle cell disease: A phase 2, open‐label study	20
Statin use is associated with improved survival in multiple myeloma: A Swedish population‐based study of 4315 patients	20
Vaccine‐induced thrombotic thrombocytopenia following Ad26.COV2.S vaccine in a man presenting as acute venous thromboembolism	19
Sequential P‐GEMOX and radiotherapy for early‐stage extranodal natural killer/T‐cell lymphoma: A multicenter study	19
The complex karyotype and chronic lymphocytic leukemia: prognostic value and diagnostic recommendations	19
Single‐agent cladribine as an effective front‐line therapy for adults with Langerhans cell histiocytosis	19
Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice	19
Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials	19
Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors	19
The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes	19
Reduced global cerebral oxygen metabolic rate in sickle cell disease and chronic anemias	19
The prognostic value of additional copies of 1q21 in multiple myeloma depends on the primary genetic event	19
Risk of invasive fungal infections in patients with high‐risk MDS and AML receiving hypomethylating agents	19
Risk factors for severe COVID‐19 in hospitalized sickle cell disease patients: A study of 319 patients in France	19
Current approaches to management of high‐risk multiple myeloma	19
Treatment of acquired hemophilia A, a balancing act: results from a 27‐year Dutch cohort study	19
Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients	19
Viscoelastic hemostatic assays: Update on technology and clinical applications	18
Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) c	18
Langerhans cell histiocytosis with lung involvement in isolation and multisystem disease: Staging, natural history, and comparative survival	18
Making hydroxyurea affordable for sickle cell disease in Tanzania is essential (HASTE): How to meet major health needs at a reasonable cost	18
Ecarin based coagulation testing	18
The impact of extended half‐life factor concentrates on prophylaxis for severe hemophilia in the United States	18
Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease	18
Tricuspid regurgitation velocity and other biomarkers of mortality in children, adolescents and young adults with sickle cell disease in the United States: The PUSH study	18
Risk of mortality from anemia and iron overload in nontransfusion‐dependent β‐thalassemia	18
Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes	18
Overall survival of patients with triple‐class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH	18
Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in VEXAS syndrome: Data from a prospective series of patients	18
Genomic characteristics and prognostic significance of co‐mutated ASXL1/SRSF2 acute myeloid leukemia	18
Aggressive T‐cell lymphomas: 2021 Updates on diagnosis, risk stratification and management	18
Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor‐naïve patients with myelofibrosis: Results of a phase II trial	17
Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses	17
Iron and platelets: A subtle, under‐recognized relationship	17
Hodgkin lymphoma: 2023 update on diagnosis, risk‐stratification, and management	17
Basiliximab for steroid‐refractory acute graft‐versus‐host disease: A real‐world analysis	17
TLR8/TLR7 dysregulation due to a novel TLR8 mutation causes severe autoimmune hemolytic anemia and autoinflammation in identical twins	17
Deciphering the individual contribution of absolute neutrophil and monocyte counts to thrombosis risk in polycythemia vera and essential thrombocythemia	17
An effective chemotherapy‐free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome‐positive acute lymphoblastic leukemia	17
Splenectomy for primary immune thrombocytopenia revisited in the era of thrombopoietin receptor agonists: New insights for an old treatment	17
Cytomegalovirus kinetics after hematopoietic cell transplantation reveal peak titers with differential impact on mortality, relapse and immune reconstitution	17
Hemolytic crisis due to Covid‐19 vaccination in a woman with cold agglutinin disease	17
CD34+ cell dose effects on clinical outcomes after T‐cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem ce	17
Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open‐label study	17
Individual red blood cell fetal hemoglobin quantification allows to determine protective thresholds in sickle cell disease	17
Intravenous high‐dose methotrexate based systemic therapy in the treatment of isolated primary vitreoretinal lymphoma: An LOC network study	17
Decitabine and venetoclax for IDH1/2‐mutated acute myeloid leukemia	17
Immune thrombocytopenia due to COVID‐19 during pregnancy	17
Daratumumab for disabling cold agglutinin disease refractory to B‐cell directed therapy	17
Tumor mutational load predicts time to first treatment in chronic lymphocytic leukemia (CLL) and monoclonal B‐cell lymphocytosis beyond the CLL international prognostic index	17
Current approaches to management of newly diagnosed multiple myeloma	16
Determination of fitness and therapeutic options in older patients with acute myeloid leukemia	16
Management of CLL patients early in the COVID‐19 pandemic: An international survey of CLL experts	16
Lovo‐cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB‐206 study	16
Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry	16
From Hematologistʼs desk: The effect of COVID‐19 on the blood system	16
A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia	16
Low‐dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs	15
Romidepsin and lenalidomide‐based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts	15
Risk factors for severe infection and mortality In patients with COVID‐19 in patients with multiple myeloma and AL amyloidosis	15
Momelotinib for myelofibrosis: 12‐year survival data and retrospective comparison to ruxolitinib	15
Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403	15
A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202)	15
Patient‐reported neurocognitive symptoms influence instrumental activities of daily living in sickle cell disease	15
Transplant eligibility in elderly multiple myeloma patients: Prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other co	15
The benefits of iron supplementation following blood donation vary with baseline iron status	15
Frontline combination of ponatinib and hyper‐CVAD in Philadelphia chromosome‐positive acute lymphoblastic leukemia: 80‐months follow‐up results	15
Outcome of adults with relapsed/refractory T‐cell acute lymphoblastic leukemia or lymphoblastic lymphoma	15
The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance	15
Characteristics of late transplant‐associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation	15
Splenectomy before allogeneic hematopoietic cell transplantation for myelofibrosis: A French nationwide study	15
CDKN2A deletions are associated with poor outcomes in 101 adults with T‐cell acute lymphoblastic leukemia	15
Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm	15
Severe thrombocytopenia and microangiopathic hemolytic anemia in pregnancy: A guide for the consulting hematologist	15
Cutaneous B‐cell lymphomas: 2021 update on diagnosis, risk‐stratification, and management	14
Haploidentical vs matched unrelated donor transplantation for acute myeloid leukemia in remission: A prospective comparative study	14
Plasma P‐selectin is an early marker of thromboembolism in COVID‐19	14
Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio	14
Improved outcomes among newly diagnosed patients with FMS‐like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the	14
Overall and complication‐free survival in a large cohort of patients with β‐thalassemia major followed over 50 years	14
The impact of granulocyte colony stimulating factor on patients receiving chimeric antigen receptor T‐cell therapy	14
Effect of age and frailty on the efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma	14
Treosulfan compared with reduced‐intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Fi	14
Depression in adolescents and young adults with heavy menstrual bleeding in a referral clinic setting	14
A novel 4‐mRNA signature predicts the overall survival in acute myeloid leukemia	13
Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real‐life campus CLL study	13
Survival analysis in treated plasmablastic lymphoma patients: a population‐based study	13
Intravenous ferric derisomaltose for the treatment of iron deficiency anemia	13